The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 23, 2025
Filed:
Sep. 02, 2020
Applicant:
Tilt Biotherapeutics Oy, Helsinki, FI;
Inventors:
Akseli Hemminki, Helsinki, FI;
Markus Vähä-Koskela, Helsinki, FI;
Siri Tähtinen, Helsinki, FI;
Vincenzo Cerullo, Helsinki, FI;
Assignee:
TILT BIOTHERAPEUTICS OY, Helsinki, FI;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/761 (2015.01); A61K 35/17 (2015.01); A61K 35/76 (2015.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); C07K 14/525 (2006.01); C07K 14/55 (2006.01); C07K 14/565 (2006.01); C07K 14/57 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 35/12 (2015.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 35/17 (2013.01); A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C07K 14/472 (2013.01); C07K 14/52 (2013.01); C07K 14/525 (2013.01); C07K 14/55 (2013.01); C07K 14/565 (2013.01); C07K 14/57 (2013.01); C12N 15/86 (2013.01); A61K 2035/124 (2013.01); A61K 48/00 (2013.01); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); C12N 2710/10032 (2013.01); C12N 2710/10041 (2013.01); C12N 2710/10043 (2013.01);
Abstract
There is disclosed oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect, there is also disclosed the separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, there is disclosed a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.